Valeant Pharmaceuticals International Selects Next-Generation Potassium-Channel Openers for Pre-Clinical Development

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has selected several pre-Investigational New Drug (IND) candidates for its next-generation potassium-channel opener program. These new compounds add to Valeant’s growing expertise with a novel and promising new class of anti-epileptic drugs. Valeant is currently conducting two pivotal Phase 3 studies for retigabine, a neuronal potassium-channel opener as an adjunctive treatment for partial-onset seizures in patients with refractory epilepsy. Potassium-channel openers are a clinically validated target for epilepsy and show potential in treating other neurological conditions such as neuropathic pain.

Back to news